Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On December 21, 2021, Simon Pedder notified Athenex, Inc. (the "Company") that
he will be resigning from his position as Chief Business and Strategy Officer,
Proprietary Products, effective as of December 31, 2021. In connection with his
resignation, the Company and Dr. Pedder entered into a consulting agreement
effective as of January 1, 2022, pursuant to which Dr. Pedder will provide
clinical development and business development related services to the Company
until July 1, 2022, unless earlier terminated. Under that agreement, Dr. Pedder
is entitled to receive $350 per hour for providing consulting services. The
foregoing description of the agreement is a summary of its material terms, does
not purport to be complete, and is qualified in its entirety by reference to the
agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on
Form 8-K and is incorporated herein by reference.
On December 22, 2021, the Company appointed Timothy Cook as Chief Business and
Commercial Officer, Proprietary Drugs. Mr. Cook, age 59, has been serving as the
Company's Senior Vice President of Global Oncology since July 2018. Prior to
joining the Company, Mr. Cook served as the Vice President and Chief Operating
Officer for Lilly Oncology from February 2017 until December 2017 after serving
in various roles of increasing responsibility beginning in November 2000.
Mr. Cook's compensation from the Company did not change in connection with his
appointment to Chief Business and Commercial Officer, Proprietary Drugs.
Mr. Cook is eligible to receive a base salary of approximately $350,000 per year
and a target annual cash incentive award equal to 40% of his base salary.
Mr. Cook was not appointed to this position pursuant to any arrangement or
understanding with any person. Neither Mr. Cook nor any of his immediate family
has been a party to any transaction with the Company, nor is any such
transaction currently proposed, that would be reportable under Item 404(a) of
Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
10.1 Consulting Agreement, dated as of January 1, 2022 between Athenex,
Inc. and Simon Pedder
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses